share_log

RenovoRx Executes Definitive Subscription Agreement With Accredited Investors For $11.1M At Market Private Placement

Benzinga ·  Apr 8 08:36
  • Cash position now expected to fund current operating plan into 2026
  • Financing provides cash runway to advance the ongoing pivotal Phase III TIGeR-PaC trial through the second interim readout and towards completion of the trial
  • Financing also enables the expansion of RenovoRx's TAMP (Trans-Arterial Micro-Perfusion) clinical development pipeline into additional cancer indications
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment